+

US20070148147A1 - Bacterial composition and its use - Google Patents

Bacterial composition and its use Download PDF

Info

Publication number
US20070148147A1
US20070148147A1 US11/594,542 US59454206A US2007148147A1 US 20070148147 A1 US20070148147 A1 US 20070148147A1 US 59454206 A US59454206 A US 59454206A US 2007148147 A1 US2007148147 A1 US 2007148147A1
Authority
US
United States
Prior art keywords
pta
lactobacillus
composition
bacterial
bacterial composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/594,542
Inventor
Veronique Dennin
Gregory Leyer
Annick Mercenier
Sophie Nutten
Bruno Pot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FOOD RHODIA
RHOD P
International N&H Denmark ApS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/310,549 external-priority patent/US7179460B2/en
Application filed by Individual filed Critical Individual
Priority to US11/594,542 priority Critical patent/US20070148147A1/en
Publication of US20070148147A1 publication Critical patent/US20070148147A1/en
Assigned to DANISCO A/S reassignment DANISCO A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DANISCO FRANCE SAS
Assigned to RHODIA CHIMIE reassignment RHODIA CHIMIE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DENNIN, VERONIQUE, LEYER, GREG, MERCENIER, ANNICK, NUTTEN, SOPHIE, POT, BRUNO
Assigned to FOOD, RHODIA reassignment FOOD, RHODIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHIMIE, RHODIA
Assigned to RHOD P. reassignment RHOD P. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FOOD, RHODIA
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/23—Lactobacillus acidophilus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum

Definitions

  • the subject of the present invention is a bacterial composition, an immunomodulation method and the use of this composition.
  • Immunomodulation is the capacity to improve the global immune functions either in healthy or in pathologic situations.
  • bacteria some have a positive influence on the immune system of the intestinal medium, in particular lactic acid bacteria and bifidobacteria, and are termed “probiotic” bacteria or strains.
  • probiotic bacteria or strains is understood to mean a strain which, when ingested live, exerts a beneficial effect on the host by having an action on the balance of the intestinal flora.
  • These probiotic strains have the capacity to survive following passage across the upper part of the digestive tube. They are non-pathogenic, non-toxic and exert a beneficial action on health through in one hand their ecological interactions with the resident flora of the digestive tract and in the other hand their ability to positively influence immune system, through their effects onto the GALT (gut associated immune tissue).
  • GALT gut associated immune tissue
  • those bacteria when given in sufficient numbers have the capacity to transit alive all along the gut. There they become part of the resident flora for the period of administration.
  • the so called colonisation allow the probiotic bacteria to exert beneficial effect, such as repression of potentially pathogen micro-organisms on the flora and interactions with the gut immune system.
  • the probiotic strains most widely used, in particular in dairy products, are mainly bacteria and yeasts, of the following genera Lactobacillus spp, Streptococcus spp, Enterococcus spp and Bifidobacteriu spp and Sacharomyces spp.
  • lactobacillus spp Streptococcus spp
  • Enterococcus spp Enterococcus spp
  • Bifidobacteriu spp and Sacharomyces spp.
  • probiotic effects reported for those bacteria one can cite for example, improvement of lactose tolerance, prevention and or treatment of gastrointestinal and urogenital infections, reduction of some cancers, decrease of blod cholesterol.
  • the problem which the present invention proposes to solve is to provide a bacterial composition having probiotic properties.
  • the aim of the present invention is to satisfy these requirements.
  • the present invention provides a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
  • Another subject of the invention is an, immunomodulation method.
  • the subject of the invention is also a food or pharmaceutical composition comprising the bacterial compositions described above.
  • Another subject of the invention is also the use of this composition in the preparation of a carrier administered to humans or to animals for a therapeutic or prophylactic purpose in the gastrointestinal system.
  • composition of the invention has the advantage of providing unquestionable virtues which enrich the range of available strains.
  • composition is particularly advantageous when it is administered to humans or to animals for a therapeutic or prophylactic purpose in the gastrointestinal system, in particular in the reduction of inflammatory and/or allergic reactions.
  • the advantage of the present invention is also to preserve all its properties when it is incorporated into a pharmaceutically acceptable carrier or into a food product.
  • the subject of the invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
  • the Lactobacillus acidophilus used according to the invention is a Gram-positive strain.
  • it is a catalase-negative strain, with a homofermentative metabolism giving rise to the production of lactic acid.
  • Lactobacillus acidophilus used according to the invention may also produce a bacteriocin, lactacin, which is active against other microorganisms.
  • it is a Lactobacillus acidophilus exhibiting good resistance to pepsin, under acidic pH conditions (about at least 73% of the bacteria are still alive after 40 minutes of treatment).
  • Lactobacillus acidophilus used according to the invention exhibits a very good resistance to pancreatin (at least 100% of the bacteria are still alive after 40 minutes of treatment).
  • the Lactobacillus acidophilus used according to the invention exhibits good tolerance to bile salts.
  • a Lactobacillus acidophilus described as being “hydrophobic”, that is to say which exhibits a high affinity for hydrophobic organic solvents, polar or not polar, such as for example n-decane, chloroform, hexadecane or xylene, will be used.
  • the Lactobacillus acidophilus used according to the invention can induce the production of cytokines.
  • This detection of the induction-of cytokines was made by means of a test for in vitro stimulation of isolated peripheral blood mononuclear cells (PBMC).
  • PBMC peripheral blood mononuclear cells
  • IL10 interleukins 10
  • ⁇ -IFN ⁇ -interferon
  • TNF ⁇ tumour necrosis factor ⁇
  • the Lactobacillus acidophilus used according to the invention induces little or no secretion of interleukins 12 (IL12) using this same test.
  • the Lactobacillus acidophilus used according to the invention is Lactobacillus acidophilus PTA-4797.
  • This Lactobacillus acidophilus strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number PTA-4797.
  • composition according to the invention is a bacterial composition comprising Lactobacillus acidophilus PTA-4797.
  • composition made of probiotic bacteria according to the invention may also comprise at least one Lactobacillus plantarum strain.
  • the Lactobacillus plantarum strain used according to the invention is preferably a. Gram-positive strain.
  • it is a catalase-negative strain, with a homofermentative metabolism giving rise to the production of lactic acid.
  • the Lactobacillus plantarum used according to the invention exhibits good resistance to pancreatin (about at least 79% of the bacteria are still alive after 40 minutes of treatment).
  • the Lactobacillus plantarum used according to the invention exhibits good resistance to bile salts.
  • the Lactobacillus plantarum used according to the invention can induce the production of cytokines.
  • This detection of the induction of cytokines was made by means of a test for in vitro stimulation of isolated peripheral blood mononuclear cells (PBMC).
  • PBMC peripheral blood mononuclear cells
  • IL10 interleukins 10
  • ⁇ -IFN ⁇ -interferon
  • TNF ⁇ tumour necrosis factor
  • the Lactobacillus plantarum used according to the invention induces. little or no secretion of interleukins 12 (IL12) using this same test.
  • the Lactobacillus plantarum used according to the invention is Lactobacillus plantarum PTA-4799.
  • This Lactobacillus plantarum strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number PTA-4799.
  • composition according to the invention is a bacterial composition comprising Lactobacillus plantarum PTA-4799.
  • composition made of probiotic ,bacteria according to the invention may also comprise at least one Lactobacillus salivarius strain.
  • the Lactobacillus salivarius strain used according to the invention is a Gram-positive strain.
  • it is a catalase-negative strain, with a homofermentative metabolism giving rise to the production of lactic acid.
  • Lactobacillus salivarius used according to the invention exhibits good resistance to pancreatin (at least 100% of the bacteria are still alive after 40 minutes of treatment).
  • the Lactobacillus salivarius used according to the invention can induce the secretion of cytokines.
  • This detection of the induction of cytokines was made by means of a test for in vitro stimulation of isolated peripheral blood mononuclear cells (PBMC).
  • PBMC peripheral blood mononuclear cells
  • IL10 interleukins 10
  • TNF ⁇ tumour necrosis factor
  • the Lactobacillus salivarius used according to the invention induces little or no secretion of interleukin 12 (IL12) and ⁇ -interferon ( ⁇ -IFN) using this same test.
  • IL12 interleukin 12
  • ⁇ -IFN ⁇ -interferon
  • the Lactobacillus salivarius used according to the invention is Lactobacillus salivarius PTA-4800.
  • This Lactobacillus salivarius strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number PTA-4800.
  • composition according to the invention is a bacterial composition comprising Lactobacillus salivarius PTA-4800.
  • composition made of probiotic bacteria according to the invention may also comprise at least one Lactobacillus paracasei strain.
  • the Lactobacillus paracasei used according to the invention is a Gram-positive strain.
  • it is a catalase-negative strain, with a homofermentative metabolism giving rise to the production of lactic acid.
  • it is a Lactobacillus paracasei exhibiting poor resistance to pepsin, under acidic pH conditions (about at least 17.5% of the bacteria are still alive after 40 minutes of treatment).
  • Lactobacillus paracasei used according to the invention exhibits a very good resistance to pancreatin (about at least 100% of the bacteria are still alive after 40 minutes of treatment.
  • the Lactobacillus paracasei used according--to the invention exhibits good tolerance to bile salts.
  • the Lactobacillus paracasei used according to the invention can induce the production of cytokines.
  • This detection of the induction of cytokines was made by means of a test for in vitro stimulation of isolated peripheral blood mononuclear cells (PBMC).
  • PBMC peripheral blood mononuclear cells
  • IL10 interleukins 10
  • ⁇ -IFN ⁇ -interferon
  • TNF ⁇ tumour necrosis factor
  • the Lactobacillus paracasei used according to the invention induces little or no secretion of interleukins 12 (IL12) using this same test.
  • the Lactobacillus paracasei used according to the invention is Lactobacillus paracasei PTA-4798.
  • This Lactobacillus paracasei strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number PTA-4798.
  • composition according to the invention is a bacterial composition comprising Lactobacillus paracasei PTA-4798.
  • composition made of probiotic bacteria according to the invention may also comprises at least one Bifidobacterium bifidum strain.
  • the Bifidobacterium bifidum strain used according to the invention is a Gram-positive strain.
  • it is a catalase-negative strain, with a heterofermentative metabolism giving rise to the production of lactic acid and acetic acid.
  • the Bifidobacterium bifidum used according to the invention is Bifidobacterium bifidum PTA-4801. This Bifidobacterium bifidum strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number ATCC PTA-4801.
  • composition according to the invention is. a bacterial composition comprising Bifidobacterium bifidum PTA-4801.
  • composition made of probiotic bacteria according to the invention may also comprises at least one Bifidobacterium lactis strain.
  • the Bifidobacterium lactis strain used according to the invention is a Gram-positive strain.
  • it is a catalase-negative strain, with a heterofermentative metabolism giving rise to the production of lactic acid and acetic acid.
  • the Bifidobacterium lactis used according to the invention is Bifidobacterium lactis PTA-4802. This Bifidobacterium lactis strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number ATCC PTA-4801.
  • composition according to the invention is a bacterial composition comprising Bifidobacterium lactis PTA-4801.
  • composition according to the invention is a bacterial composition comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, and Bifidobacterium lactis PTA-4802.
  • composition according to the invention may comprise at least 2 strains selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
  • composition according to the invention may comprise 3 strains selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
  • the composition according to the invention may comprise a blend of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium lactis PTA-4802 and Bifidobacterium bifidum PTA-4801.
  • composition according to the invention may be used in the form of a bacterial suspension, before or after freezing, or of a freeze-dried powder. Indeed, regardless of the form. used, the composition may be frozen.
  • the relative proportion of each bacterium in the composition can vary in large limit for example from 1/99 to 99/1 in the case there is at least 2 strains.
  • composition according to the invention may comprise from 10 6 to 10 11 CFU of bacteria/g of composition, and more particularly from 10 8 to 10 11 CFU of bacteria/g of composition.
  • CFU means “colony forming units”.
  • the expression gram of composition is understood to mean the food product or pharmaceutical preparation, and preferably 10 9 to 10 11 CFU/g if in a freeze-dried form.
  • composition according to the invention is useful for the treatment, the primary prevention or the recurrence, and also the prevention and/or the reduction of inflammatory bowel disease.
  • the bacterial composition according to the invention is also useful for maintaining the homeostasis of the immune system.
  • the bacterial composition according to the invention is also useful for the prevention and/or the reduction of allergenicity.
  • the bacterial composition according to the invention is also useful as immunoadjuvent.
  • An other subject of the invention is also an immunomodulation method comprising the step of using at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
  • composition according to the invention may be used in the form of a food product or pharmaceutical preparation.
  • the expression pharmaceutical preparation is understood to mean for example a preparation in the form of capsule or tablet.
  • the subject of the invention is also a food, dietary supplement or pharmaceutical composition comprising the bacterial composition described above.
  • the food composition comprising the composition according to the invention is a food supplements, a beverage product or a milk base powder.
  • the food composition comprising the composition according to the invention is a dairy product.
  • the food composition comprising the composition according to the invention is an infant formula.
  • the food or pharmaceutical composition according to the invention may have immunomodulation properties.
  • Another subject- of the invention- is also the use of this composition in the preparation of a carrier administered to humans or to animals for a therapeutic or prophylactic purpose in the gastrointestinal system.
  • the invention provides also a pharmaceutical composition comprising the bacterial composition described above useful for the prevention of inflammatory bowel disease.
  • the invention provides also a pharmaceutical composition comprising the bacterial composition described above useful for immunomodulation.
  • FIGS. 1, 3 and 5 are schedules of injection.
  • FIGS. 2, 4 and 6 are Wallace and Ameho scores, and weight of loss.
  • PBMC Peripheral Blood Mononuclear Cells
  • Bacteria are prepared according to standard conditions and counted-by plating on agarose medium according to proper dilutions (10 ⁇ 7 , 10 ⁇ 8 , 10 ⁇ 9 in Ringer solution).
  • PBMC cells are stimulated for 48 hours with the bacteria (allow negative control with Phosphate Buffer Saline solution (PBS)) under appropriate conditions of CO 2 . Then the supernatant containing the cytokines is frozen at ⁇ 20° C.
  • PBS Phosphate Buffer Saline solution
  • Cytokines expression levels are determined by ELISA tests ( ⁇ Enzyme linked immuno sorbent assay>>). ELISA plates are coated with anti-cytokine antibody (overnight procedure) and the antibody is blocked with a surfactant, the tween 80.
  • a proper standard is prepared for known concentrations of cytokines which will cover the detection range of 15.62 till 2000 pg/ml (incubate overnight). Perform the anti-cytokine detection and quantify with streptavidine reaction on substrate (10 mg dABTS/10 ml of citric acid buffer 0.1 M, pH 4.35/20 ⁇ l H2O2).
  • Cytokines are either pro-inflammatory/Th1 (TNF ⁇ , IFN ⁇ , IL12) or anti-inflammatory (IL10).
  • TNF ⁇ pro-inflammatory/Th1
  • IFN ⁇ IFN ⁇
  • IL12 anti-inflammatory
  • Strains IL-10 IL-12 IFN- ⁇ TNF- ⁇ L. acidophilus PTA-4797 309 1970 27591 L. salivarius PTA-4800 6881 31 1148 23509 L. paracasei PTA-4798 300 31 921 14046 The values are pg/ml.
  • a blend of 3 strains is prepared containing Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, et Bifidobacterium lactis PTA-4802. This blend is named LAB.
  • TNBS trinitrobenzene sulfonic acid, which is a colitis inducing agent
  • LAB intake of bacteria
  • effects which are scored on day 22, according to standard scores (Wallace and Ameho respectively).
  • a second model of chronic colitis was also used (based on Camoglio et al., Eur J Immunol 2000), 2 mg/mice of TNBS injected by intra-rectal route on days 0, 7, and 14 induce a serious chronic colitis.
  • the schedule of injection is drawn on figure. 3.
  • the intake of bacteria (LAB) on days ⁇ 5 to ⁇ 1, on days 5 and 12 ( FIG. 3 ) will show macroscopic and histological effects, which are scored on day 16, according to standard scores (Wallace and Ameho respectively).
  • mice colitis was also set up. 100 mg/kg mice of TNBS is injected on day 0. This will evoke an acute colitis. The schedule of injection is drawn on FIG. 5 .
  • the intake of Bifidobacterium lactis PTA-4802 or Lactobacillus plantarum PTA-4799 (10 7 bacteria/mouse) on days ⁇ 5 to 0 show macroscopic and histological effects which are scored on day 2.
  • mice show that feeding LAB to these mice significantly reduced the level of intestinal translocation of indigenous bacteria from the intestinal flora into mesenteric lymph nodes and spleen after the induction of colitis.
  • no translocation of probiotic bacterial strains according to the invention was observed.
  • the aim of this test is to evaluate the resistance of bacteria to the passage of the gastric barrier by determining the number of bacteria that survive after cultivation in the presence of a pepsin. solution in acid environment.
  • 100 ⁇ of a stock culture frozen at ⁇ 80° C. is inoculated in 10 ml of MRS (Man Rogosa Sharp) culture medium and incubated overnight at 30° C. or 37° C.
  • MRS Man Rogosa Sharp
  • cells are washed 3 times in PBS at pH7 and the pellet is suspended in 1 ml PBS buffered and inoculated in 200 ⁇ l aliquots in 4 tubes with 1 ml of filtered pepsin solution at pH 2 supplemented with 300 ⁇ l of NaCl (0.5%).
  • Cell count is performed on 100 ⁇ l aliquots taken from the tubes incubated at T0 (time of inoculation), T0+5min; T0+20min; T0+40min; T0+60min and dilutions are plated on MRS (100 ⁇ l) of 10 5, 10 6 et 10 7 (consecutive 10 fold dilutions made in 1 ml Ringer solution). The percentage surviving bacteria is. calculated for each incubation time from the reading of the dilution series.
  • the aim of this test is to evaluate the resistance of bacteria to the passage of the intestinal transit by determining the number of bacteria that survive after cultivation in the presence of a pancreatin solution in basic environment.
  • 100 ⁇ l of a stock culture frozen at ⁇ 80° C. is inoculated in 10 ml of MRS (Man Rogosa Sharp) culture medium and incubated overnight at 30° C. or 37° C.
  • Cells are washed 3 times in PBS at pH7 and the pellet is suspended in 1 ml PBS buffered and inoculated in 200 ⁇ l aliquots in 4 tubes with 1 ml of filtered pancreatin. solution at pH 8 supplemented with 300 ⁇ l of NaCl (0.5%).
  • Cell count is performed on 100 ⁇ l aliquots taken from the tubes incubated at T0(time of inoculation), T0+5min; T0+20min; T0+40min; T0+60min;
  • T0+120min and dilutions are plated on MRS (100 ⁇ l) of 10 5, 10 6, 10 7 (consecutive 10 fold dilutions made in 1 ml Ringer solution). The percentage surviving bacteria is calculated for each incubation. time from the reading of the dilution series. All results displayed in the tables are the result of triplicate experiments.
  • Strains 5 min 20 min 40 min 60 min 120 min L. acidophilus PTA-4797 83 100 100 170 170 L. salivarius PTA-4800 100 115 152 158 155 L. plantarum PTA-4799 86 72 79 84 87 L. paracasei PTA-4798 65 100 100 100 100 100 100 100 Results as % of survival compared to T 0.
  • Results are coded as sensitive (0 ; more than 60 minutes), tolerant (1 ; between 15 and 60 minutes) or resistant (2 ; less than 15 minutes).
  • the test measures (grown overnight under normal in vitro growth conditions and washed twice in PBS) the hydrophobicity and polarity of the bacterial cell wall, based on the repartition (measured by optical density) of the bacteria into two non mixable liquid aqueous phases and five respective solvents.
  • Growth medium is MRS (Man Rogosa Sharp) and the aqueous phase is a buffer as. PBS.
  • the solvents were decane, hexadecane, ethyl acetate, chloroform and xylene.
  • the affinity for apolar solvents (decane, hexadecane, xylene) reflects the hydrophobic character of the bacterium.
  • hydrophobicity is related to the presence of glycoproteins on the cell- wall surface, while a low hydrophobicity could be linked to the presence of polysaccharides on the cell wall surface.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is an immunomodulation method comprising the step of using the at least one strain selected from the preceding group.

Description

  • The subject of the present invention is a bacterial composition, an immunomodulation method and the use of this composition. Immunomodulation is the capacity to improve the global immune functions either in healthy or in pathologic situations.
  • Among bacteria, some have a positive influence on the immune system of the intestinal medium, in particular lactic acid bacteria and bifidobacteria, and are termed “probiotic” bacteria or strains.
  • The expression probiotic bacteria or strains is understood to mean a strain which, when ingested live, exerts a beneficial effect on the host by having an action on the balance of the intestinal flora. These probiotic strains have the capacity to survive following passage across the upper part of the digestive tube. They are non-pathogenic, non-toxic and exert a beneficial action on health through in one hand their ecological interactions with the resident flora of the digestive tract and in the other hand their ability to positively influence immune system, through their effects onto the GALT (gut associated immune tissue). According to the probiotic definition, those bacteria when given in sufficient numbers have the capacity to transit alive all along the gut. There they become part of the resident flora for the period of administration. The so called colonisation (or transcient colonisation) allow the probiotic bacteria to exert beneficial effect, such as repression of potentially pathogen micro-organisms on the flora and interactions with the gut immune system.
  • The probiotic strains most widely used, in particular in dairy products, are mainly bacteria and yeasts, of the following genera Lactobacillus spp, Streptococcus spp, Enterococcus spp and Bifidobacteriu spp and Sacharomyces spp. Among the probiotic effects reported for those bacteria, one can cite for example, improvement of lactose tolerance, prevention and or treatment of gastrointestinal and urogenital infections, reduction of some cancers, decrease of blod cholesterol. However, it should be highlighted that not all the individual strains from the genera described above have those effects, but only some carefully selected strains do.
  • Thus in order to satisfy the requirements for performant probiotic strains, it has become necessary to select strains or a mixture thereof which is efficient and which allow stimulation of the immune system (immunomodulation).
  • Accordingly, the problem which the present invention proposes to solve is to provide a bacterial composition having probiotic properties.
  • The aim of the present invention is to satisfy these requirements.
  • For this purpose, the present invention provides a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
  • Another subject of the invention is an, immunomodulation method.
  • The subject of the invention is also a food or pharmaceutical composition comprising the bacterial compositions described above.
  • Another subject of the invention is also the use of this composition in the preparation of a carrier administered to humans or to animals for a therapeutic or prophylactic purpose in the gastrointestinal system.
  • The composition of the invention has the advantage of providing unquestionable virtues which enrich the range of available strains.
  • Such a composition is particularly advantageous when it is administered to humans or to animals for a therapeutic or prophylactic purpose in the gastrointestinal system, in particular in the reduction of inflammatory and/or allergic reactions.
  • The advantage of the present invention is also to preserve all its properties when it is incorporated into a pharmaceutically acceptable carrier or into a food product.
  • Other advantages and characteristics of the present invention will emerge more clearly on reading the description and the examples given purely by way of illustration and without limitation, which follow.
  • First of all, the subject of the invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
  • The Lactobacillus acidophilus used according to the invention is a Gram-positive strain. Advantageously, it is a catalase-negative strain, with a homofermentative metabolism giving rise to the production of lactic acid.
  • The Lactobacillus acidophilus used according to the invention may also produce a bacteriocin, lactacin, which is active against other microorganisms.
  • Preferably,. it is a Lactobacillus acidophilus exhibiting good resistance to pepsin, under acidic pH conditions (about at least 73% of the bacteria are still alive after 40 minutes of treatment).
  • More particularly, the Lactobacillus acidophilus used according to the invention exhibits a very good resistance to pancreatin (at least 100% of the bacteria are still alive after 40 minutes of treatment).
  • Advantageously, the Lactobacillus acidophilus used according to the invention exhibits good tolerance to bile salts.
  • Preferably, a Lactobacillus acidophilus described as being “hydrophobic”, that is to say which exhibits a high affinity for hydrophobic organic solvents, polar or not polar, such as for example n-decane, chloroform, hexadecane or xylene, will be used.
  • The Lactobacillus acidophilus used according to the invention can induce the production of cytokines. This detection of the induction-of cytokines was made by means of a test for in vitro stimulation of isolated peripheral blood mononuclear cells (PBMC). Among the cytokines induced during this test, there may be mentioned interleukins 10 (IL10), γ-interferon (γ-IFN) and tumour necrosis factor α (TNFα). On the other hand, the Lactobacillus acidophilus used according to the invention induces little or no secretion of interleukins 12 (IL12) using this same test.
  • The Lactobacillus acidophilus used according to the invention is Lactobacillus acidophilus PTA-4797. This Lactobacillus acidophilus strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number PTA-4797.
  • One embodiment of the composition according to the invention is a bacterial composition comprising Lactobacillus acidophilus PTA-4797.
  • The composition made of probiotic bacteria according to the invention may also comprise at least one Lactobacillus plantarum strain.
  • The Lactobacillus plantarum strain used according to the invention is preferably a. Gram-positive strain. Advantageously, it is a catalase-negative strain, with a homofermentative metabolism giving rise to the production of lactic acid.
  • Preferably, it is a Lactobacillus plantarum which is resistant to pepsin under acidic pH conditions (about at least. 95% of the bacteria are still alive after 40 minutes-of treatment). More particularly, the Lactobacillus plantarum used according to the invention exhibits good resistance to pancreatin (about at least 79% of the bacteria are still alive after 40 minutes of treatment).
  • Advantageously, the Lactobacillus plantarum used according to the invention exhibits good resistance to bile salts.
  • The Lactobacillus plantarum used according to the invention can induce the production of cytokines. This detection of the induction of cytokines was made by means of a test for in vitro stimulation of isolated peripheral blood mononuclear cells (PBMC). Among the cytokines induced during this test, there may be. mentioned interleukins 10 (IL10), γ-interferon (γ-IFN) and tumour necrosis factor α(TNFα). On the other hand, the Lactobacillus plantarum used according to the invention induces. little or no secretion of interleukins 12 (IL12) using this same test.
  • The Lactobacillus plantarum used according to the invention is Lactobacillus plantarum PTA-4799. This Lactobacillus plantarum strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number PTA-4799.
  • One embodiment of the composition according to the invention is a bacterial composition comprising Lactobacillus plantarum PTA-4799.
  • The composition made of probiotic ,bacteria according to the invention may also comprise at least one Lactobacillus salivarius strain.
  • The Lactobacillus salivarius strain used according to the invention is a Gram-positive strain. Advantageously, it is a catalase-negative strain, with a homofermentative metabolism giving rise to the production of lactic acid.
  • More particularly, the Lactobacillus salivarius used according to the invention exhibits good resistance to pancreatin (at least 100% of the bacteria are still alive after 40 minutes of treatment).
  • The Lactobacillus salivarius used according to the invention can induce the secretion of cytokines. This detection of the induction of cytokines was made by means of a test for in vitro stimulation of isolated peripheral blood mononuclear cells (PBMC). Among the cytokines induced during this test, there may be mentioned interleukins 10 (IL10) and tumour necrosis factor α(TNFα). On the other hand, the Lactobacillus salivarius used according to the invention induces little or no secretion of interleukin 12 (IL12) and γ-interferon (γ-IFN) using this same test.
  • The Lactobacillus salivarius used according to the invention is Lactobacillus salivarius PTA-4800. This Lactobacillus salivarius strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number PTA-4800.
  • One embodiment of the composition according to the invention is a bacterial composition comprising Lactobacillus salivarius PTA-4800.
  • The composition made of probiotic bacteria according to the invention may also comprise at least one Lactobacillus paracasei strain.
  • The Lactobacillus paracasei used according to the invention is a Gram-positive strain. Advantageously, it is a catalase-negative strain, with a homofermentative metabolism giving rise to the production of lactic acid.
  • Preferably, it is a Lactobacillus paracasei exhibiting poor resistance to pepsin, under acidic pH conditions (about at least 17.5% of the bacteria are still alive after 40 minutes of treatment).
  • More particularly, the Lactobacillus paracasei used according to the invention exhibits a very good resistance to pancreatin (about at least 100% of the bacteria are still alive after 40 minutes of treatment.
  • Advantageously, the Lactobacillus paracasei used according--to the invention exhibits good tolerance to bile salts.
  • The Lactobacillus paracasei used according to the invention can induce the production of cytokines. This detection of the induction of cytokines was made by means of a test for in vitro stimulation of isolated peripheral blood mononuclear cells (PBMC). Among the cytokines induced during this test, there may be mentioned interleukins 10 (IL10), γ-interferon (γ-IFN) and tumour necrosis factor α(TNFα). On the other hand, the Lactobacillus paracasei used according to the invention induces little or no secretion of interleukins 12 (IL12) using this same test.
  • The Lactobacillus paracasei used according to the invention is Lactobacillus paracasei PTA-4798. This Lactobacillus paracasei strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number PTA-4798.
  • One embodiment of the composition according to the invention is a bacterial composition comprising Lactobacillus paracasei PTA-4798.
  • The composition made of probiotic bacteria according to the invention may also comprises at least one Bifidobacterium bifidum strain.
  • The Bifidobacterium bifidum strain used according to the invention is a Gram-positive strain. Advantageously, it is a catalase-negative strain, with a heterofermentative metabolism giving rise to the production of lactic acid and acetic acid.
  • The Bifidobacterium bifidum used according to the invention is Bifidobacterium bifidum PTA-4801. This Bifidobacterium bifidum strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number ATCC PTA-4801.
  • One embodiment of the composition according to the invention is. a bacterial composition comprising Bifidobacterium bifidum PTA-4801.
  • The composition made of probiotic bacteria according to the invention may also comprises at least one Bifidobacterium lactis strain.
  • The Bifidobacterium lactis strain used according to the invention is a Gram-positive strain. Advantageously, it is a catalase-negative strain, with a heterofermentative metabolism giving rise to the production of lactic acid and acetic acid.
  • The Bifidobacterium lactis used according to the invention is Bifidobacterium lactis PTA-4802. This Bifidobacterium lactis strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number ATCC PTA-4801.
  • One embodiment of the composition according to the invention is a bacterial composition comprising Bifidobacterium lactis PTA-4801.
  • Another embodiment of the composition according to the invention is a bacterial composition comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, and Bifidobacterium lactis PTA-4802.
  • More particularly, the composition according to the invention may comprise at least 2 strains selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
  • More particularly, the composition according to the invention may comprise 3 strains selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
  • Preferably, the composition according to the invention may comprise a blend of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium lactis PTA-4802 and Bifidobacterium bifidum PTA-4801.
  • The composition according to the invention may be used in the form of a bacterial suspension, before or after freezing, or of a freeze-dried powder. Indeed, regardless of the form. used, the composition may be frozen.
  • The relative proportion of each bacterium in the composition can vary in large limit for example from 1/99 to 99/1 in the case there is at least 2 strains.
  • The composition according to the invention. may comprise from 106 to 1011 CFU of bacteria/g of composition, and more particularly from 108 to 1011 CFU of bacteria/g of composition. The term CFU means “colony forming units”. The expression gram of composition is understood to mean the food product or pharmaceutical preparation, and preferably 109 to 1011 CFU/g if in a freeze-dried form.
  • The composition according to the invention is useful for the treatment, the primary prevention or the recurrence, and also the prevention and/or the reduction of inflammatory bowel disease.
  • The bacterial composition according to the invention is also useful for maintaining the homeostasis of the immune system.
  • The bacterial composition according to the invention is also useful for the prevention and/or the reduction of allergenicity.
  • The bacterial composition according to the invention is also useful as immunoadjuvent.
  • An other subject of the invention is also an immunomodulation method comprising the step of using at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
  • The composition according to the invention may be used in the form of a food product or pharmaceutical preparation.
  • The expression pharmaceutical preparation is understood to mean for example a preparation in the form of capsule or tablet.
  • The subject of the invention is also a food, dietary supplement or pharmaceutical composition comprising the bacterial composition described above.
  • Preferably, the food composition comprising the composition according to the invention is a food supplements, a beverage product or a milk base powder.
  • More particularly, the food composition comprising the composition according to the invention is a dairy product.
  • More preferably the food composition comprising the composition according to the invention is an infant formula.
  • The food or pharmaceutical composition according to the invention may have immunomodulation properties.
  • Another subject- of the invention- is also the use of this composition in the preparation of a carrier administered to humans or to animals for a therapeutic or prophylactic purpose in the gastrointestinal system.
  • The invention provides also a pharmaceutical composition comprising the bacterial composition described above useful for the prevention of inflammatory bowel disease.
  • The invention provides also a pharmaceutical composition comprising the bacterial composition described above useful for immunomodulation.
  • The FIGS. 1, 3 and 5 are schedules of injection.
  • The FIGS. 2, 4 and 6 are Wallace and Ameho scores, and weight of loss.
  • Concrete but nonlimiting examples of the invention will now be described.
    • EXAMPLES 1/PBMC Test
  • PBMC (Peripheral Blood Mononuclear Cells) are prepared by centrifugation from human blood, derived from known donors and is further purified on a Ficoll gradient. Cells are harvested, washed, (red blood cells removed) and counted.
  • Bacteria are prepared according to standard conditions and counted-by plating on agarose medium according to proper dilutions (10−7, 10−8, 10−9 in Ringer solution).
  • Cells are washed 3 times and suspended (et non dissolved) in PBS buffer. A verifier par Dominique
  • PBMC cells are stimulated for 48 hours with the bacteria (allow negative control with Phosphate Buffer Saline solution (PBS)) under appropriate conditions of CO2. Then the supernatant containing the cytokines is frozen at −20° C.
  • Cytokines expression levels are determined by ELISA tests (<<Enzyme linked immuno sorbent assay>>).ELISA plates are coated with anti-cytokine antibody (overnight procedure) and the antibody is blocked with a surfactant, the tween 80.
  • A proper standard is prepared for known concentrations of cytokines which will cover the detection range of 15.62 till 2000 pg/ml (incubate overnight). Perform the anti-cytokine detection and quantify with streptavidine reaction on substrate (10 mg dABTS/10 ml of citric acid buffer 0.1 M, pH 4.35/20 μl H2O2).
  • Cytokines are either pro-inflammatory/Th1 (TNFα, IFNγ, IL12) or anti-inflammatory (IL10).
    Strains IL-10 IL-12 IFN-γ TNF-α
    L. acidophilus PTA-4797 309 1970 27591
    L. salivarius PTA-4800 6881 31 1148 23509
    L. paracasei PTA-4798 300 31 921 14046

    The values are pg/ml.
    • 2/Preparation of a Composition Made of Lactobacillus acidophillus PTA-4797, Lactobacillus plantarum PTA-4799 and Bifidobacterium lactis PTA-4802.
  • A blend of 3 strains is prepared containing Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, et Bifidobacterium lactis PTA-4802. This blend is named LAB.
  • To show in vivo, the immuno modulation capacity of this blend according to the invention, animal test were performed aimed at decreasing the chemically induced gut inflammation of mice. Several models were set-up to mimic human inflammatory bowel- diseases.
  • In the first model, injections of 1 mg/mice of TNBS (trinitrobenzene sulfonic acid, which is a colitis inducing agent) on days 0, 7 and 14, and 2 mg/mice of TNBS on day 20 (double dose) will evoke a chronic colitis. The schedule of injection is drawn on FIG. 1. The intake of bacteria (LAB) on days −4 to −1, 6, 9, 13 and 19 will show macroscopic and histological. effects, which are scored on day 22, according to standard scores (Wallace and Ameho respectively).
  • The results obtained (see FIG. 2) clearly showed an improvement of the colitis symptoms evidenced by
      • reduction of the increase of the submucosa
      • reduction of the inflammation
      • less weight loss
  • A second model of chronic colitis was also used (based on Camoglio et al., Eur J Immunol 2000), 2 mg/mice of TNBS injected by intra-rectal route on days 0, 7, and 14 induce a serious chronic colitis. The schedule of injection is drawn on figure. 3. The intake of bacteria (LAB) on days −5 to −1, on days 5 and 12 (FIG. 3) will show macroscopic and histological effects, which are scored on day 16, according to standard scores (Wallace and Ameho respectively).
  • The results obtained clearly showed an improvement of the colitis symptoms evidenced (see FIG. 4) by
      • absence of necrotic lesions
      • reduction of the increase of the submucosa
      • reduction of the inflammation
  • A third acute model of mice colitis was also set up. 100 mg/kg mice of TNBS is injected on day 0. This will evoke an acute colitis. The schedule of injection is drawn on FIG. 5. The intake of Bifidobacterium lactis PTA-4802 or Lactobacillus plantarum PTA-4799 (107 bacteria/mouse) on days −5 to 0 show macroscopic and histological effects which are scored on day 2.
  • Clear macroscopic improvement of the colitis symptoms were evidenced for strains Bifidobacterium lactis PTA-4802 and Lactobacillus plantarum PTA-4799 (FIG. 6).
  • In general all the TNBS-induced colitis models in mice show that feeding LAB to these mice significantly reduced the level of intestinal translocation of indigenous bacteria from the intestinal flora into mesenteric lymph nodes and spleen after the induction of colitis. In addition, no translocation of probiotic bacterial strains according to the invention was observed.
    • 3/Resistance to Pepsin
  • The aim of this test is to evaluate the resistance of bacteria to the passage of the gastric barrier by determining the number of bacteria that survive after cultivation in the presence of a pepsin. solution in acid environment. In short, 100 μof a stock culture frozen at −80° C. is inoculated in 10 ml of MRS (Man Rogosa Sharp) culture medium and incubated overnight at 30° C. or 37° C. Then cells are washed 3 times in PBS at pH7 and the pellet is suspended in 1 ml PBS buffered and inoculated in 200 μl aliquots in 4 tubes with 1 ml of filtered pepsin solution at pH 2 supplemented with 300 μl of NaCl (0.5%). Cell count is performed on 100 μl aliquots taken from the tubes incubated at T0 (time of inoculation), T0+5min; T0+20min; T0+40min; T0+60min and dilutions are plated on MRS (100 μl) of 105, 10 6 et 107 (consecutive 10 fold dilutions made in 1 ml Ringer solution). The percentage surviving bacteria is. calculated for each incubation time from the reading of the dilution series.
  • All results displayed in the tables are the result of triplicate experiments
    Strains 5 min 20 min 40 min 60 min
    L. acidophilus PTA-4797 91 74 73 55
    L. plantarum PTA-4799 100 100 95 42
    L. salivarius PTA-4800 100 66 23 7
    L. paracasei PTA-4798 100 17.5 17.5 1.5

    Results as % of survival compared to T=0.
    • 4/Resistance to Pancreatin
  • The aim of this test is to evaluate the resistance of bacteria to the passage of the intestinal transit by determining the number of bacteria that survive after cultivation in the presence of a pancreatin solution in basic environment. In short, 100 μl of a stock culture frozen at −80° C. is inoculated in 10 ml of MRS (Man Rogosa Sharp) culture medium and incubated overnight at 30° C. or 37° C. Cells are washed 3 times in PBS at pH7 and the pellet is suspended in 1 ml PBS buffered and inoculated in 200 μl aliquots in 4 tubes with 1 ml of filtered pancreatin. solution at pH 8 supplemented with 300 μl of NaCl (0.5%). Cell count is performed on 100 μl aliquots taken from the tubes incubated at T0(time of inoculation), T0+5min; T0+20min; T0+40min; T0+60min;
  • T0+120min and dilutions are plated on MRS (100 μl) of 105, 10 6, 10 7 (consecutive 10 fold dilutions made in 1 ml Ringer solution). The percentage surviving bacteria is calculated for each incubation. time from the reading of the dilution series. All results displayed in the tables are the result of triplicate experiments.
    Strains 5 min 20 min 40 min 60 min 120 min
    L. acidophilus PTA-4797 83 100 100 170 170
    L. salivarius PTA-4800 100 115 152 158 155
    L. plantarum PTA-4799 86 72 79 84 87
    L. paracasei PTA-4798 65 100 100 100 100

    Results as % of survival compared to T=0.
    • 5/Resistance to Bile Salts
  • The experimental is procedure is as follows. 100 μl culture of a stock frozen at −80° C. is inoculated in 10 ml de milieu de culture MRS (Man Rogosa Sharp)and incubated overnight at 30° C. or 37° C. The optical density(OD) is measured and a dilution is prepared (OD=0.05 to 0.1) in two bottles. One of the culture bottles is supplemented with a 0.3% solution of bile salts (750 μl of a filtered 12% solution ) and incubated at the correct temperature. The OD is regularly measured until a OD of 0.3 is reached in the control bottle without bile salts. At that point the OD of the supplemented bottle is measured and one starts to measure the time needed to obtain the same OD of 0.3. The resistance of-the strain is therefore evaluated as the delay in growth time.
  • Results are coded as sensitive (0 ; more than 60 minutes), tolerant (1 ; between 15 and 60 minutes) or resistant (2 ; less than 15 minutes).
  • All results displayed in the tables are the results of triplicate experiments
    Strains Resistance
    L. acidophilus PTA-4797 1
    L. plantarum PTA-4799 2
    L. paracasei PTA-4798 2
    • 6/Hydrophobicity and Affinity for Organic Solvents
  • The MATS test as described by Rosdenberg et al., 1980 (FEMS Microbiol. Letters 9 ;29-33) has been used. In short the test measures (grown overnight under normal in vitro growth conditions and washed twice in PBS) the hydrophobicity and polarity of the bacterial cell wall, based on the repartition (measured by optical density) of the bacteria into two non mixable liquid aqueous phases and five respective solvents. Growth medium is MRS (Man Rogosa Sharp) and the aqueous phase is a buffer as. PBS. The solvents were decane, hexadecane, ethyl acetate, chloroform and xylene.
  • The affinity for chloroform, acid solvent, reflects the electron donor nature of the bacterium
  • (Basic Reaction)
  • The affinity for Ethyl Acetate, basic solvent, reflects the electron acceptor nature of the bacterium
  • (Acid Reaction)
  • The affinity for apolar solvents (decane, hexadecane, xylene) reflects the hydrophobic character of the bacterium.
  • Possibly a high hydrophobicity is related to the presence of glycoproteins on the cell- wall surface, while a low hydrophobicity could be linked to the presence of polysaccharides on the cell wall surface.
  • % D'HYDROPHOBICITY=(1−A/AO)×100 with
      • AO: Original OD at 540 nm (set more or less at OD=0.6 in PBS)
  • A: Optical density of aqeous phase (for 1 ml) after vortexing and stabilisation period
    Hexa- Ethyl Chloro-
    Strains Decane decane acetate form Xylene
    L. acidophilus PTA-4797 81.9 60.4 44.2 90.3 90.9
    L. salivarius PTA-4800 23.02 38.17 2.25 79.28 51.18
    L. paracasei PTA-4798 36.5 37.4 28.8 45.2 30.6
    L. plantarum PTA-4799 25.3 25.6 28.7 28.8 21.9

Claims (19)

1-21. (canceled)
22. A bacterial composition having immunomodulation properties comprising Lactobacillus acidophilus PTA4797.
23. The bacterial composition according to claim 22 comprising at least one additional strain selected from the group consisting of Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798 and Bifidobacterium bifidum PTA-4801.
24. The bacterial composition according to claim 22 comprising at least two additional strains selected from the group consisting of Lactobacillus acidophilus, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA4800, Lactobacillus paracasei PTA-4798 and Bifidobacterium bifidum PTA-4801.
25. The bacterial composition according to claim 22 comprising a blend of Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA4800, Lactobacillus paracasei PTA-4798, Bifdobacterium lactis PTA-4802 and Bifidobacterium bifidum PTA-4801.
26. The bacterial composition according to claim 22, comprising from 106 to 1011 CFU of bacteria/g of composition.
27. The bacterial composition according to claim 26, comprising from 108 to 1011 CFU of bacteria/g of composition.
28. A process for the prevention or the reduction of inflammatory bowel disease, comprising the step of administering to a human or an animal an efficient preventing or reducing amount of inflammatory bowel disease, of a bacterial composition as defined in claim 22.
29. A process for maintaining the homeostatis of the immune system comprising the step of administering to a human or an animal an efficient maintaining amount of the homeostasis of the immune system, of a bacterial composition as defined in claim 22.
30. A process for the prevention or the reduction of allergenicity comprising the step of administering to a human or an animal an efficient preventing or reducing amount of allergenicity, of a bacterial composition as defined in claim 22.
31. An immunoadjuvent composition, comprising a bacterial composition as defined in claim 22.
32. An immunomodulation method comprising the step of using Lactobacillus acidophilus PTA-4797.
33. A food, dietary supplement or pharmaceutical composition comprising a composition as defined in claim 22.
34. The composition according to claim 33, being in the form of a dairy product.
35. The composition according to claim 34, being in the form of an infant formula.
36. The composition of claim 34, having immunomodulation properties.
37. A pharmaceutical composition comprising the composition as defined in claim 22 for the prevention of inflammatory bowel disease.
38. The immunomodulation method according to claim 32, further comprising at least one additional strain selected from the group consisting of Lactobacillus plantarum PTA4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, and Bifidobacterium bifidum PTA4801.
39. A pharmaceutical composition comprising the composition as defined in claim 22 for immunomodulation.
US11/594,542 2002-12-05 2006-11-08 Bacterial composition and its use Abandoned US20070148147A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/594,542 US20070148147A1 (en) 2002-12-05 2006-11-08 Bacterial composition and its use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/310,549 US7179460B2 (en) 2002-12-05 2002-12-05 Bacterial composition and its use
US11/594,542 US20070148147A1 (en) 2002-12-05 2006-11-08 Bacterial composition and its use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/310,549 Division US7179460B2 (en) 2002-12-05 2002-12-05 Bacterial composition and its use

Publications (1)

Publication Number Publication Date
US20070148147A1 true US20070148147A1 (en) 2007-06-28

Family

ID=38194038

Family Applications (7)

Application Number Title Priority Date Filing Date
US11/594,542 Abandoned US20070148147A1 (en) 2002-12-05 2006-11-08 Bacterial composition and its use
US11/594,543 Expired - Lifetime US7740838B2 (en) 2002-12-05 2006-11-08 Bacterial composition and its use
US12/778,509 Expired - Fee Related US8071086B2 (en) 2002-12-05 2010-05-12 Bacterial composition and its use
US13/283,778 Abandoned US20120135036A1 (en) 2002-12-05 2011-10-28 Bacterial composition and its use
US14/493,710 Abandoned US20150079041A1 (en) 2002-12-05 2014-09-23 Bacterial composition and its use
US15/457,205 Abandoned US20180028581A1 (en) 2002-12-05 2017-03-13 Bacterial composition and its use
US16/298,035 Abandoned US20200009202A1 (en) 2002-12-05 2019-03-11 Bacterial composition and its use

Family Applications After (6)

Application Number Title Priority Date Filing Date
US11/594,543 Expired - Lifetime US7740838B2 (en) 2002-12-05 2006-11-08 Bacterial composition and its use
US12/778,509 Expired - Fee Related US8071086B2 (en) 2002-12-05 2010-05-12 Bacterial composition and its use
US13/283,778 Abandoned US20120135036A1 (en) 2002-12-05 2011-10-28 Bacterial composition and its use
US14/493,710 Abandoned US20150079041A1 (en) 2002-12-05 2014-09-23 Bacterial composition and its use
US15/457,205 Abandoned US20180028581A1 (en) 2002-12-05 2017-03-13 Bacterial composition and its use
US16/298,035 Abandoned US20200009202A1 (en) 2002-12-05 2019-03-11 Bacterial composition and its use

Country Status (1)

Country Link
US (7) US20070148147A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014421A1 (en) * 2007-07-25 2009-01-29 Campina Nederland Holding B.V. Probiotics for inducing satiety and/or satiation
WO2009048934A2 (en) 2007-10-11 2009-04-16 Danisco A/S Probiotics for use in relieving symptoms associated with gastrointestinal disorders
US20110189149A1 (en) * 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
CN102597214A (en) * 2009-07-22 2012-07-18 Cj第一制糖株式会社 Novel lactobacillus plantarum and composition comprising same
CN102597216A (en) * 2009-10-28 2012-07-18 Cj第一制糖株式会社 Novel lactobacillus plantarum and composition comprising the same
CN108969513A (en) * 2018-09-12 2018-12-11 大理大学 A kind of foundation and application of syndrome of stagnation of liver qi and spleen deficiency Animal Model of Ulcerative Colitis
CN112063565A (en) * 2020-09-23 2020-12-11 山东环亿生物科技有限公司 Inactivated lactobacillus agent and preparation method and application thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101075558B1 (en) * 2008-12-03 2011-10-20 씨제이제일제당 (주) Novel Lactobacillus plantarum and compositions comprising the same
KR101075557B1 (en) * 2008-12-03 2011-10-20 씨제이제일제당 (주) Novel Lactobacillus plantarum and compositions comprising the same
KR101255050B1 (en) 2009-07-14 2013-04-16 씨제이제일제당 (주) Novel lactobacillus plantarum and compositions comprising the same
TW201106957A (en) * 2009-08-31 2011-03-01 Synbio Tech Inc The new strain of Lactobacillus plantarum LP28 and its use in treating allergy
WO2011059332A2 (en) 2009-11-16 2011-05-19 Stichting Top Institute Food And Nutrition Improved immunomodulation by probiotics
US9113653B2 (en) 2011-08-19 2015-08-25 Steven J Maranz Methods of administering probiotic organisms that synthesize carotenoid compounds in situ to enhance human health and nutrition
CN104694409B (en) * 2013-12-06 2017-11-17 深圳华大基因科技有限公司 Lactobacillus plantarum and application thereof
US11617771B2 (en) 2016-12-15 2023-04-04 The Regents Of The University Of California Oral composition comprising lactic acid bacteria for regulating immune responses and methods related thereto
CN107058159B (en) * 2016-12-29 2021-06-08 石家庄君乐宝乳业有限公司 Lactobacillus plantarum JMCC0017 with good survivability in milk beverage, screening method and application thereof
CN111235070B (en) * 2020-03-18 2022-03-08 河北农业大学 Breast milk infant source lactobacillus plantarum BF _15 and application thereof
CN117979982A (en) * 2021-07-22 2024-05-03 国际营养与健康丹麦私人有限公司 Probiotics for enhancing the immune system

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858356A (en) * 1995-12-21 1999-01-12 Abbott Laboratories Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals
US6033691A (en) * 1996-06-13 2000-03-07 Sancor Cooperativas Unidas Limitada Process for manufacturing a biologically active fermented milk product and product obtained by the process
US6241983B1 (en) * 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US6294166B1 (en) * 1997-03-24 2001-09-25 Viva Life Science, Inc. Nutrition supplement containing Lactobacillus acidophilus, yeast and soy protein
US20020006432A1 (en) * 1999-01-15 2002-01-17 Collins John Kevin Bifidobacterium in the treatment of inflammatory disease
US6379663B1 (en) * 1997-08-21 2002-04-30 New Zealand Dairy Board Immunity enhancing lactic acid bacteria
US6419926B2 (en) * 1997-04-11 2002-07-16 Ghen Corporation Specific antibodies for use in preparation of pharmaceutical compositions useful in the prevention or treatment of gastritis, gastric ulcers and duodenal ulcers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2031586C1 (en) * 1993-02-05 1995-03-27 Тамара Георгиевна Извекова Biologically active product of sour milk and method for its production
AUPO758297A0 (en) * 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
AU2001272369A1 (en) * 2000-07-17 2002-01-30 Chr. Hansen A/S Methods and formultations with probiotic microorganisms and medicaments

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6241983B1 (en) * 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US5858356A (en) * 1995-12-21 1999-01-12 Abbott Laboratories Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals
US6033691A (en) * 1996-06-13 2000-03-07 Sancor Cooperativas Unidas Limitada Process for manufacturing a biologically active fermented milk product and product obtained by the process
US6294166B1 (en) * 1997-03-24 2001-09-25 Viva Life Science, Inc. Nutrition supplement containing Lactobacillus acidophilus, yeast and soy protein
US6419926B2 (en) * 1997-04-11 2002-07-16 Ghen Corporation Specific antibodies for use in preparation of pharmaceutical compositions useful in the prevention or treatment of gastritis, gastric ulcers and duodenal ulcers
US6379663B1 (en) * 1997-08-21 2002-04-30 New Zealand Dairy Board Immunity enhancing lactic acid bacteria
US20020006432A1 (en) * 1999-01-15 2002-01-17 Collins John Kevin Bifidobacterium in the treatment of inflammatory disease

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014421A1 (en) * 2007-07-25 2009-01-29 Campina Nederland Holding B.V. Probiotics for inducing satiety and/or satiation
US20100203026A1 (en) * 2007-07-25 2010-08-12 Campina Nederland Holding B.V. Probiotics for inducing satiety and/or satiation
WO2009048934A2 (en) 2007-10-11 2009-04-16 Danisco A/S Probiotics for use in relieving symptoms associated with gastrointestinal disorders
WO2009048934A3 (en) * 2007-10-11 2009-10-29 Danisco A/S Probiotics for use in relieving symptoms associated with gastrointestinal disorders
US20110033423A1 (en) * 2007-10-11 2011-02-10 Gregory Leyer Probiotics for use in relieving symptoms associated with gastrointestinal disorders
US9055763B2 (en) 2007-10-11 2015-06-16 Dupont Nutrition Biosciences Aps Probiotics for use in relieving symptoms associated with gastronitestinal disorders
US20110189149A1 (en) * 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
CN102597214A (en) * 2009-07-22 2012-07-18 Cj第一制糖株式会社 Novel lactobacillus plantarum and composition comprising same
CN102597216A (en) * 2009-10-28 2012-07-18 Cj第一制糖株式会社 Novel lactobacillus plantarum and composition comprising the same
CN108969513A (en) * 2018-09-12 2018-12-11 大理大学 A kind of foundation and application of syndrome of stagnation of liver qi and spleen deficiency Animal Model of Ulcerative Colitis
CN112063565A (en) * 2020-09-23 2020-12-11 山东环亿生物科技有限公司 Inactivated lactobacillus agent and preparation method and application thereof

Also Published As

Publication number Publication date
US8071086B2 (en) 2011-12-06
US20100322964A1 (en) 2010-12-23
US20120135036A1 (en) 2012-05-31
US20070148148A1 (en) 2007-06-28
US7740838B2 (en) 2010-06-22
US20150079041A1 (en) 2015-03-19
US20200009202A1 (en) 2020-01-09
US20180028581A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
US20200009202A1 (en) Bacterial composition and its use
AU2003298411B2 (en) Composition comprising lactobacilli or bifidobacteria and use thereof
Servin Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens
CN101744841B (en) Bifidobacteria for the treatment of inflammatory diseases
Lidbeck et al. Lactobacilli and the normal human anaerobic microflora
US5494664A (en) Bifidobacteria
Famularo et al. Stimulation of immunity by probiotics
US11052122B2 (en) Lactic bacteria and their use in the prevention of diarrhea
KR102146429B1 (en) Strain of bifidobacterium animalis ssp. animalis
Tomičić et al. Beneficial properties of probiotic yeast Saccharomyces boulardii
Kolida et al. Gastrointestinal microflora: probiotics
JPWO2009066537A1 (en) Immunoregulatory function inducer and food composition
Kalliomäki et al. Positive interactions with the microbiota: probiotics
JP4308481B2 (en) Antiallergic agent
Kim et al. Antitumor activity of Lactobacillus plantarum cytoplasm on teratocarcinoma-bearing mice
Abdel-Megeed Therapeutic impact of probiotics in various aspects
BG112471A (en) Immunomodulating synbiotic composition
Mandal Study of Lactobacillus Isolates from Human Sources with regard to Their Beneficial Physiological Attributes
Beccati Investigations of prebiotics and of inter-and intra-molecular glycan-protein interactions
BG2759U1 (en) Immunomoduling synbiotic composition
Bruno The Lactobacillus species

Legal Events

Date Code Title Description
AS Assignment

Owner name: FOOD, RHODIA, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHIMIE, RHODIA;REEL/FRAME:019662/0175

Effective date: 20070527

Owner name: RHOD P., FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FOOD, RHODIA;REEL/FRAME:019662/0609

Effective date: 20040426

Owner name: DANISCO A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DANISCO FRANCE SAS;REEL/FRAME:019662/0968

Effective date: 20050427

Owner name: RHODIA CHIMIE, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DENNIN, VERONIQUE;LEYER, GREG;MERCENIER, ANNICK;AND OTHERS;REEL/FRAME:019662/0692

Effective date: 20030218

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载